Abstract
Abstract Development of CAR T-cell therapies for T-cell lymphoma has been hampered by a limited range of targetable antigens. Shared expression of most T-lineage antigens between malignant and normal T cells promotes fratricide of CAR T cells and increases the risk of T-cell aplasia. We developed a CAR targeting CD5, a pan-T cell antigen commonly expressed in T-cell lymphoma. CD5 CAR T cells evade fratricide by rapidly downregulating CD5 protein expression and retain high cytotoxicity against T-cell lymphoma. An ongoing phase I clinical trial demonstrates curative potential of autologous CD5 CAR T cells in patients with peripheral T-cell lymphoma. CD5 CAR T-cell infusions were well tolerated and did not produce prolonged ablation of endogenous T cells. Other CAR T cell-based approaches for T-cell lymphoma will also be discussed. Citation Format: Maksim Mamonkin. CAR T cells for T-cell lymphoma [abstract]. In: Proceedings of the AACR Virtual Meeting: Advances in Malignant Lymphoma; 2020 Aug 17-19. Philadelphia (PA): AACR; Blood Cancer Discov 2020;1(3_Suppl):Abstract nr IA17.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
